eli lilly glp-1 agonist launches pill, kicking off showdown with Novo Nordisk What's Coming Next for GLP-1

We also consider the effect of these molecules on other obesity-related complications [glycaemia in people with T2D and on liver fat content in people with MASLD/metabolic dysfunction-associated steatohepatitis (MASH, previously known as non-alcoholic steatohepatitis)] and we discuss the potential clinical implications and challenges that the new era in obesity pharmacotherapy will bring

More recently, researchers have been testing GLP-1 receptor agonists in people with obesity

Verify if they support community or conservation projects

Novo Nordisks acquisition of Catalent manufacturing facilities, valued at approximately US$11 billion, highlights the importance of production capacity in the GLP-1 market

doi: 10.1002/osp4.124

Glucagon-like peptide-1 (GLP-1) agonists are a class of medications frequently used to treat type 2 diabetes mellitus (T2DM) and obesity.[1] This class of medications assists in lowering blood sugar levels and promotes weight loss